Paul Ruh Chief Financial Officer First Quarter 2025 Earnings Results May 8, 2025 Introduction Sofya Tsinis Vice President of Investor Relations 3 Thibaut Mongon Chief Executive Officer Cautionary note on forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements about management's expectations of Kenvue's future operating and financial performance, product development, market ...

Full-Year Fiscal 2025 Results May 8th, 2025 Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, and free cash flow; the Company's reinvestment in Clear Eyes as supply increases; the Company's ability to execute on its brand- building strategy and to drive free cash flo ...

Company Overview - Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to CD&R, while retaining a 48.2% stake [1] - The transaction generated approximately €10 billion in net cash proceeds for Sanofi [1] Opella's Position and Strategy - Opella is now an independent global leader in consumer healthcare, positioned for long-term success with a strong brand portfolio and international reach [3][5] - The company employs over 11,000 people and operates in 100 countries, with 13 manufacturing sites and four development centers [5] - Opella is the third-largest player in the OTC and vitamins, minerals & supplements market, serving over half a billion consumers globally [5] Future Outlook - CD&R aims to support Opella in becoming a global consumer health champion, leveraging its expertise in the consumer health sector [4] - Opella is focused on unlocking its full potential and driving value creation through innovation and exceptional talent [5]

Core Viewpoint - Prestige Consumer Healthcare Inc. is set to release its fiscal 2025 fourth quarter and year-end earnings on May 8, 2025, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results [1]. Company Overview - Prestige Consumer Healthcare Inc. markets, sells, manufactures, and distributes a wide range of consumer healthcare products across the U.S., Canada, Australia, and other international markets [4]. - The company's diverse portfolio includes well-known brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon® in Canada, Hydralyte®, and the Fess® line of products in Australia [4].